Ginkgetin exerts growth inhibitory and apoptotic effects on osteosarcoma cells through inhibition of STAT3 and activation of caspase-3/9

Oncology Reports

Volumn 35, Issue 2, 2016, Pages 1034-1040

  Xiong, Min ^a   Wang, Lin ^a   Yu, Hua Long ^a   Han, Heng ^a   Mao, Dan ^a   Chen, Jie ^a   Zeng, Yun ^a   He, Ning ^a   Liu, Zhi Gang ^a   Wang, Zhi Yong ^a   Xu, Shou Jia ^a   Guo, Le Yun ^a   Wang, Yong An ^a  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Caspase 3 9; Ginkgetin; Osteosarcoma; STAT3

Indexed keywords

CASPASE 3; CASPASE 9; FLAVONE DERIVATIVE; GINKGETIN; LACTATE DEHYDROGENASE; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; BIFLAVONOID; BIRC5 PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CYCLIN D1; INHIBITOR OF APOPTOSIS PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL X; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LACTATE DEHYDROGENASE ASSAY; MTT ASSAY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE TUMOR; CELL DIVISION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; PROTO ONCOGENE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BIFLAVONOIDS; BONE NEOPLASMS; CASPASE 3; CASPASE 9; CELL DIVISION; CELL LINE, TUMOR; CYCLIN D1; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-1; GENES, BCL-2; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASM PROTEINS; OSTEOSARCOMA; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; STAT3 TRANSCRIPTION FACTOR;

EID: 84954306670     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4427     Document Type: Article

References (26)

1. Bacci G, Gherlinzoni F, Picci P, et al: Adriamycin-methotrexate high dose versus adriamycin-methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities: a randomized study. Eur J Cancer Clin Oncol 22: 1337-1345, 1986.
2. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, Pape H, Dunst J, Kahn T, Willers R, et al: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 11: 1451-1462, 2000.
3. Kong CB, Kim MS, Lee SY, Cho WH, Song WS, Lee JA, Yoo JY, Chung SH and Jeon DG: Prognostic effect of diaphyseal location in osteosarcoma: A cohort case-control study at a single institute. Ann Surg Oncol 16: 3094-3100, 2009.
4. Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, et al; Italian and Scandinavian Sarcoma Groups: Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localize1d osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 23: 8845-8852, 2005.
5. Lee JA, Choi SY, Kang HJ, Lee JW, Kim H, Kim JH, Sung KW, Shin HY, Ahn HS and Park KD: Treatment outcome of osteosarcoma after bilateral retinoblastoma: A retrospective study of eight cases. Br J Ophthalmol 98: 1355-1359, 2014.
6. Su Y, Sun CM, Chuang HH and Chang PT: Studies on the cytotoxic mechanisms of ginkgetin in a human ovarian adenocarcinoma cell line. Naunyn Schmiedebergs Arch Pharmacol 362: 82-90, 2000.
7. Wang YQ, Wang MY, Fu XR, Peng-Yu, Gao GF, Fan YM, Duan XL, Zhao BL, Chang YZ and Shi ZH: Neuroprotective effects of ginkgetin against neuro-injury in Parkinson's disease model induced by MPTP via chelating iron. Free Radic Res: Jul 1, 2015 (Epub ahead of print).
8. Lim H, Son KH, Chang HW, Kang SS and Kim HP: Effects of anti-inflammatory biflavonoid, ginkgetin, on chronic skin inflammation. Biol Pharm Bull 29: 1046-1049, 2006.
9. Zhang Y, Shi S, Wang Y and Huang K: Target-guided isolation and purification of antioxidants from Selaginella sinensis by offline coupling of DPPH-HPLC and HSCCC experiments. J Chromatogr B Analyt Technol Biomed Life Sci 879: 191-196, 2011.
10. You OH, Kim SH, Kim B, Sohn EJ, Lee HJ, Shim BS, Yun M, Kwon BM and Kim SH: Ginkgetin induces apoptosis via activation of caspase and inhibition of survival genes in PC-3 prostate cancer cells. Bioorg Med Chem Lett 23: 2692-2695, 2013.
11. Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, Asano N and Takeyama M: Prognostic factors in elderly osteosarcoma patients: A multi-institutional retrospective study of 86 cases. Ann Surg Oncol 21: 263-268, 2014.
12. Boye K, Del Prever AB, Eriksson M, Saeter G, Tienghi A, Lindholm P, Fagioli F, Skjeldal S, Ferrari S and Hall K S: High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study. Pediatr Blood Cancer 61: 840-845, 2014.
13. Wang X, Goldstein D, Crowe PJ and Yang JL: Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Res 34: 6537-6545, 2014.
14. Salas S, Jiguet-Jiglaire C, Campion L, Bartoli C, Frassineti F, Deville JL, Maues De Paula A, Forest F, Jézéquel P, Gentet JC, et al: Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer 14: 606, 2014.
15. Chen H, Aksoy I, Gonnot F, Osteil P, Aubry M, Hamela C, Rognard C, Hochard A, Voisin S, Fontaine E, et al: Reinforcement of STAT3 activity reprogrammes human embryonic stem cells to naive-like pluripotency. Nat Commun 6: 7095, 2015.
16. Yu H, Lee H, Herrmann A, Buettner R and Jove R: Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat Rev Cancer 14: 736-746, 2014.
17. Liu J, Wei W, Guo CA, Han N, Pan JF, Fei T and Yan ZQ: Stat3 upregulates leucine-rich repeat-containing g protein-coupled receptor 4 expression in osteosarcoma cells. Biomed Res Int 2013: 310691, 2013.
18. Jeon YJ, Jung SN, Yun J, Lee CW, Choi J, Lee YJ, Han DC and Kwon BM: Ginkgetin inhibits the growth of DU-145 prostate cancer cells through inhibition of signal transducer and activator of transcription 3 activity. Cancer Sci 106: 413-420, 2015.
19. Huang J, Lyu H, Wang J and Liu B: MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res 5: 20-31, 2015.
20. Nemec KN and Khaled AR: Therapeutic modulation of apoptosis: Targeting the BCL-2 family at the interface of the mitochondrial membrane. Yonsei Med J 49: 689-697, 2008.
21. Rautureau GJ, Day CL and Hinds MG: Intrinsically disordered proteins in bcl-2 regulated apoptosis. Int J Mol Sci 11: 1808-1824, 2010.
22. Jiang L, Wang P, Chen L and Chen H: Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells. Int J Clin Exp Pathol 7: 5450-5460, 2014.
23. Ma YP, Zou P, Xiao J and Huang SA: Expression of survivin in cord blood CD34+ stem/progenitor cells and its significance. Zhonghua Xue Ye Xue Za Zhi 24: 238-240, 2003 (In Chinese).
24. Langelier MF and Pascal JM: PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. Curr Opin Struct Biol 23: 134-143, 2013.
25. Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, Curtin NJ, Durkacz BW, Newell DR, Porteous JK, et al: Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des 10: 507-514, 1995.
26. Yang F, Nam S, Zhao R, Tian Y, Liu L, Horne DA and Jove R: A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling. Cancer Biol Ther 14: 1024-1031, 2013.